Virtual Library

Start Your Search

Hojoong Kim



Author of

  • +

    ES 07 - Recent Advances in Diagnostics and Interventional Bronchoscopy (ID 516)

    • Event: WCLC 2017
    • Type: Educational Session
    • Track: Pulmonology/Endoscopy
    • Presentations: 1
    • +

      ES 07.03 - Bronchoscopic Management of Central Airway Obstruction (ID 7612)

      11:00 - 12:30  |  Presenting Author(s): Hojoong Kim

      • Abstract
      • Presentation
      • Slides

      Abstract:
      Introduction: Malignant airway obstruction can result from primary airway tumors, extension of adjacent primary tumors, or metastatic tumors. Partial or complete airway obstruction can deteriorate functional status of patients and result in impending respiratory failure. Malignant airway obstruction is considered to be one of the most distressing causes of morbidity and mortality in lung cancer patients. Bronchoscopic intervention can provide immediate relief from suffocation, improve general condition, and provide a bridge, allowing time for additional treatment such as surgery, radiation, or chemotherapy in patients suffering from malignant airway obstruction. Indication: Any patients who suffer from respiratory distress due to central airway obstruction are indicated for bronchoscopic intervention. However, patients should tolerate the morbidity of intervention, the length of the airway obstruction less than 4cm, and the duration of obstruction less than 2 month due to the technical limitation. Method: Due to it is safe from massive hemoptysis and respiratory failure, most experienced bronchoscopists prefer rigid bronchoscopy under general anesthesia, using intravenous propofol injection. After the induction of anesthesia, the patients are intubated with a rigid bronchoscope tube and a flexible bronchoscope is introduced through the rigid bronchoscope tube, and the narrowed central airway was evaluated. In every case, the obstructed airway is dilated gently using an 10 mm rigid bronchoscope tube initially and then progressively larger bronchoscope tubes until an adequate airway caliber was established. When indicated, a controlled radial expansion balloon is used to enlarge the airway sufficiently to allow bronchoscopic dilatation. Any intraluminal mass is removed mechanically using rigid bronchoscopic forceps or a snare. Frequently, a neodymium-yttrium aluminum garnet (Nd-YAG) or diode laser is used to ablate the residual endobronchial tumor or to cauterize the tumor bed after most of the tumor had been excised. After mechanical dilatation, the airway is maintained by inserting a silicone stent (Dumon-style stent) in patients whose airway is not maintained due to extrinsic compression or malacia. The silicone stents are inserted through the rigid bronchoscope using a standard Dumon technique. Outcome: In experienced center, the overall success rate is more than 90% after the emergency bronchoscopic intervention. A successful outcome is accompanied by subjective improvement in the symptoms and radiographic findings. After stabilizing the airway with the bronchoscopic treatment, favorable outcome is expected if additional definitive therapy can be applied, such as surgery, radiation, or chemotherapy. Nowadays, bronchoscopic intervention can achieve prolonged survival with sustained significant improvement of quality of life. Complications: Tracheal perforation, massive bleeding, respiratory failure and cardiac arrhythmia can develop after bronchoscopic intervention. However, the overall complication rate is not over 5% in experienced center. Conclusion: Bronchoscopic intervention in patients with malignant airway obstruction is helpful for the palliation the airway, allowing the multimodality therapeutic approach and prolonging the life of the patients. References 1. Jeon K, Kim H, Yu CM, et al. Rigid bronchoscopic intervention in patients with respiratory failure caused by malignant central airway obstruction. J Thorac Oncol 2006;1:319-323. 2. Cavaliere S, Venuta F, Foccoli P, et al. Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest 1996;110:1536-1542. 3. Han CC, Prasetyo D, Wright GM. Endobronchial palliation using Nd:YAG laser is associated with improved survival when combined with multimodal adjuvant treatments. J Thorac Oncol 2007;2:59-64. 4. Chhajed PN, Eberhardt R, Dienemann H, et al. Therapeutic bronchoscopy interventions before surgical resection of lung cancer. Ann Thorac Surg 2006;81:1839-1843. 5. Stratakos G, Gerovasili V, Dimitropoulos C, et al. J Cancer. 2016;25: 794-802.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.04 - Clinical Design, Statistics and Clinical Trials (ID 720)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Clinical Design, Statistics and Clinical Trials
    • Presentations: 1
    • +

      P3.04-011 - A Prospective Study to Optimize the Extent of Pulmonary Resection According to Decision-Making Algorithm in cStage IA NSCLC (ID 10047)

      09:30 - 16:00  |  Author(s): Hojoong Kim

      • Abstract
      • Slides

      Background:
      Recent advances in imaging technology and the widespread use of low-dose computed tomography screening have greatly increased the chance of detecting small-sized non-small cell lung cancer (NSCLC) with indolent features (radiologically ground-glass opacity and histopathologically lepidic pattern adenocarcinoma). This change in the disease pattern of NSCLC has led to a resurgence of interest in sublobar resection. The purpose of this study is to determine the outcome of patients with clinical stage IA NSCLC treated by 3 types of surgical resection (wide wedge resection, segmentectomy, or lobectomy) according to the institutional decision-making algorithm.

      Method:
      In this study, we are planning to prospectively enroll 1,000 patients with clinical stage IA NSCLC undergoing curative-intent surgical resection. Our decision-making algorithm regarding the optimal extent of pulmonary resection has been developed based on our institutional consensus building meetings. We are planning to prospectively measure radiologic features such as tumor diameter and consolidation/tumor (CT) ratio. For ≤ 2cm tumors with CT ratio of ≤ 0.25, wide wedge resection needs to be performed. For ≤ 2cm tumors with CT ratio of 0.25 to 0.5 or 2-3cm tumors with CT ratio of ≤ 0.5, segmentectomy should be chosen. When CT ratio is larger than 0.5, lobectomy is required regardless of tumor size. When either parenchymal or bronchial resection margin is found to be insufficient during surgery, segmentectomy or lobectomy should be done even when a lesser resection was planned. Resection margins greater than the maximal tumor diameter (lesions less than 2cm) or at least 2cm gross margins (lesions larger than 2cm) should be achieved. Hilar and mediastinal lymph node dissection or at least systematic lymph node sampling is strongly recommended for any kind of pulmonary resection.

      Result:
      The primary objective is to determine disease-free survival following sublobar resection and lobectomy. The secondary objectives are (1) to determine overall survival following surgery, (2) to determine rates of loco-regional and systemic recurrence following surgery, (3) to compare postoperative pulmonary function between 3 different resection types, (4) to explore the relationship between radiologic parameters and pathologic subtypes, and (5) to determine the predictors of unexpected nodal involvement.

      Conclusion:
      This study is registered with ClinicalTrials.gov, number NCT03066297 (“OREX-IA” study) and we started recruiting patients in February, 2017 and will also be planning to follow up patients for at least 5 years to analyze their survival and recurrences.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.